BME100 f2014:Group10 L1

From OpenWetWare

(Redirected from BME100 s2014:Group10 L1)
Jump to: navigation, search
BME 100 Fall 2014 Home
People
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Photos
Wiki Editing Help
Image:BME494_Asu_logo.png

Contents

OUR TEAM

Name: Cera Lange
Name: Cera Lange
Name: Meredith Bothman
Name: Meredith Bothman

LAB 1 WRITE-UP

Independent and Dependent Variables

Independent Variable: The independent variable is the dosages of Lipopolysaccharide. In our experiment, it will be increments of 2 starting from 0 and ending at 10mg.


Dependent Variable: The dependent variable is inflammatin. We will be measuring how much of the inflammatory protein will be produced at each increment.

Experimental Design

Groups
The subjects should initially be divided into six groups. They should be dosed with 0 mg, 2 mg, 4 mg, 6 mg, 8 mg, and 10 mg of LPS. This increment size allows for a narrowing down of the appropriate dosage, without requiring an excessive amount of trials. Once a the smallest effective dosage among the initial groups is found, more tests should be done with a reduction in increment size to accurately pinpoint the minimum dosage. A control group dosed with 0 mg should be included to account for the placebo effect. A group should also be dosed with the accepted amount of 10 mg to ensure that at least one of the groups is affected by the drug in the case that 9 or 10 mg is the minimum effective dosage.

Age
The age group that will be tested will be from ages 65 and up.


Number of subjects per group
We decided on groups of 10 giving us 60 subjects in total. We believe that a sample size of 60 subjects gives us enough data points to accurately judge the amount of inflammatin produced in the bigger population.





Subject Selection

Since the experiment tests the drug's influence on the elderly, random subjects from the ages of 65 to 95 should be chosen, and should also be chosen from different geographic areas to rule out various immune system differences. The subjects should all be healthy to reduce the possibility of error caused by agents who create various immune responses.





Sources of Error and Bias

The sick subjects could possibly be producing inflammotin already, so healthy subjects are chosen to reduce error from outside immune responses. Older patients obviously have weakened immune systems, so patients of various ages should be chosen to reflect the broader audience of the drug. Also, some patients may have an undesirable genetic or family history that may cause them to experience unique immune responses; as a result, patients with a healthier immune system would be favored. Other sources of error could come from our calculations and our measurements.







Personal tools